Good post Dwud....
First of all, of course i predicted a further price drop. That is why i sold??? If i thought it would go up short term, i would have kept my shares, right? And, i was correct. I sold 40% of my shares at .83 and 40% at .81, and it hit .665 intra-day yesterday, (which i did not get my 15% filled at .68). I am simply averaging down based on the information i have collected and the perceived near short term future.
Now, back to information. There is absolutely no way, IMO, that Medify can penetrate 10% of the market. Per Medify's website, there are ONLY 90,000 doctors in the NHS. They will be the first to test/use the product. Even IF every doctor tests this product out for the first year, that is only 6% penetration. We know EVERY doctor will not test it. Also, the majority of the trusts have NOT been presented to. Not only do the trusts need to schedule a presentation, sit through and absorb a demenstration, they also then need to meet and discuss the presentation and decide if they would like to use it for a period of time on trial to see if they find the device useful, or find it cumbersome, complicated and too expensive. Remmeber, older phyisicians are conservative. And lastly, the NHS is similar to the US Government. Things run very, very, very slowly and must go through multiple tiers with each decision. In final, i am not sure who is telling you that 10% penetration of patient notes is still on schedule, but i find it extremely hard to beleive based on information i have collected, and based on misinformation stated in previous articles.
As a note, i count 'within first year' as the time Medify Solutions went public. If they have not had a revenue contract yet with MedifyRemote (0% penetration), do you still think the can obtain 10% in next 8 months?
I think a much more conservative number may be within three years, and a realistic number may be two years.
AI
Market Data 
Markets 
